These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 30612387)

  • 1. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
    Ye C; Zheng L; Yuan CH
    Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pancreatic Cancer Microenvironment.
    Dougan SK
    Cancer J; 2017; 23(6):321-325. PubMed ID: 29189327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
    Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
    Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for pancreatic ductal adenocarcinoma.
    Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
    J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
    Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy.
    Gleeson FC; Levy MJ; Jackson RA; Murphy SJ; Halling KC; Kipp BR; Graham RP; Zhang L
    Pancreatology; 2020 Mar; 20(2):229-238. PubMed ID: 31831392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and pancreatic ductal adenocarcinoma.
    Yamasaki A; Yanai K; Onishi H
    Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies.
    Jin Y; Christenson ES; Zheng L; Li K
    Expert Rev Clin Immunol; 2024 Aug; 20(8):945-958. PubMed ID: 38690749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies].
    Yuan M; Abuduhaibaier S; Ren SQ; Zheng ZHENG; Yuan CH
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(12):831-835. PubMed ID: 33789362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
    Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
    Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic ductal adenocarcinoma microenvironment: Soluble factors and cancer associated fibroblasts as modulators of NK cell functions.
    Carlomagno S; Setti C; Ortolani F; Sivori S
    Immunol Lett; 2024 Oct; 269():106898. PubMed ID: 39019404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreas adenocarcinoma: novel therapeutics.
    Krantz BA; Yu KH; O'Reilly EM
    Chin Clin Oncol; 2017 Jun; 6(3):30. PubMed ID: 28705007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    Tan E; El-Rayes B
    J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
    Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
    J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on Pancreatic Cancer Microenvironment.
    Pratticò F; Garajová I
    Curr Oncol; 2024 Jul; 31(8):4241-4260. PubMed ID: 39195299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.